Mechanisms of antiangiogenic-induced arterial hypertension

Current Hypertension Reports

Volumn 13, Issue 4, 2011, Pages 289-293

  Mourad, Jean Jacques ^a   Levy, Bernard I ^b  

^a AVICENNE HOSPITAL   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Angiogenesis inhibitors; Antiangiogenics; Arterial hypertension; Blood pressure; Chemotherapy; Microcirculation; Tumors; Vascular endothelial growth factor; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; LINIFANIB; NITRIC OXIDE; TELATINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD PRESSURE; CAPILLARY DENSITY; CARDIOVASCULAR EFFECT; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; EXPERIMENTAL MODEL; HUMAN; HYPERTENSION; METASTASIS; NONHUMAN; PROTEIN FUNCTION; SIDE EFFECT; SOLID TUMOR; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; BLOOD PRESSURE; CAPILLARIES; DISEASE PROGRESSION; HEMODYNAMICS; HUMANS; HYPERTENSION; MICROCIRCULATION; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052597321     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-011-0206-y     Document Type: Article

References (41)

1. Pepper MS. Manipulating angiogenesis: from basic science to the bedside. Arterioscler Thromb Vasc Biol. 1997;17:605-19. (Pubitemid 27169120)
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-64. (Pubitemid 26272076)
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-6.
4. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727-39. (Pubitemid 37328908)
5. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611. (Pubitemid 39099316)
6. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795-803. (Pubitemid 37328914)
7. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35-52. (Pubitemid 38821812)
8. Longo R, Sarmiento R, Fanelli M, et al. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis. 2004;5:237-56.
9. Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol. 2006;24:1329-31. (Pubitemid 46621994)
10. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med. 2008;358:95-7.
11. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354 (9):980-2.
12. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006;63 (10):1475-8. (Pubitemid 44547561)
13. Hood JD, Meininger CJ, Ziche M, et al. VEGF upregulates eNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274:H1054-8.
14. Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem. 1999;274:33057-63. (Pubitemid 129535347)
15. Zou AP, Cowley AW. Role of nitric oxide in the control of renal function and salt sensitivity. Curr Hypertens Rep. 1999;1(2):178-86.
16. Feihl F, Liaudet L, Waeber B, Levy BI. Hypertension. A disease of the microcirculation? Hypertension. 2006;48:1012-7.
17. Struyker-Boudier HA, le Noble JL, Slaaf DW, et al. Microcirculatory changes in cremaster muscle during early spontaneous hypertension in the rat. J Hypertens Suppl. 1988;6(4):S185-7. (Pubitemid 19067311)
18. Harper RN, Moore MA, Marr MC, et al. Arteriolar rarefaction in the conjunctiva of human essential hypertensives. Microvasc Res. 1978;16:369-72. (Pubitemid 9133984)
19. Horowitz JR, Rivard A, van der Zee R, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxidedependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol. 1997;17:2793-800. (Pubitemid 28016023)
20. Kamba T, Tam BY, Hashizume H et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560-H576.
21. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35-52. (Pubitemid 38821812)
22. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol. 2006;290:H547-59.
23. Kamba T, McDonald DM. Mechanisms of adverse effects of anti- VEGF therapy for cancer. Br J Cancer. 2007;96:1788-95. (Pubitemid 46912024)
24. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19:927-34. (Pubitemid 351627309)
25. Steeghs N, Gelderblom H, Roodt JO et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008; 14: 3470-3476. This is the first paper to correlate blood pressure rise with capillary rarefaction.
26. Ruedemann AD. Conjunctival vessels. J Am Med Assoc. 1933;101:1477-81.
27. Sullivan JM, Prewitt RL, Josephs JA. Attenuation of the microcirculation in young patients with high-output borderline hypertension. Hypertension. 1983;5:844-51. (Pubitemid 14214817)
28. Serne EH, Gans ROB, ter Maaten JC, et al. Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction. Hypertension. 2001;38:238-42. (Pubitemid 34224751)
29. Antonios TFT, Singer DRJ, Markandu ND, et al. Structural skin capillary rarefaction in essential hypertension. Hypertension. 1999;33:998-1001. (Pubitemid 29186398)
30. Prasad A, Dunnill GS, Mortimer PS, MacGregor GA. Capillary rarefaction in the forearm skin in essential hypertension. J Hypertens. 1995;13:265-8.
31. Debbabi H, Uzan L, Mourad JJ, et al. Increased skin capillary density in treated essential hypertensive patients. Am J Hypertens. 2006;19:477-83.
32. Noon JP, Walker BR, Webb DJ, et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest. 1997;99:1873-9. (Pubitemid 27175934)
33. Lee PC, Salyapongse AN, Bragdon GA, et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol. 1999;277:H1600-8. (Pubitemid 29522694)
34. Dulak J, Jozkowicz A, Dembinska-Kiec A, et al. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000;20:659-66. (Pubitemid 30151678)
35. Kiefer FN, Misteli H, Kalak N, et al. Inhibition of NO biosynthesis, but not elevated blood pressure, reduces angiogenesis in rat models of secondary hypertension. Blood Press. 2002;11:116-24. (Pubitemid 34537522)
36. Prewitt RL, Hashimoto H, Stacy DL. Structural and functional rarefaction of microvessels in hypertension. In: Lee R, editor. Blood vessel changes in hypertension: structure and function. Boca Raton: CRC Press; 1990. p. 71-90.
37. Steeghs N, Rabelink TJ, op 't Roodt J, et al. Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol. 2010 ;21(5):1100-1105. This study demonstrated for the first time that bevacizumab-induced decrease in capillary density is reversible and that assessment of capillary density during treatment with antiangiogenic drugs may be useful as a marker of treatment efficacy.
38. Franklin PH, Banfor PN, Tapang P, et al. Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869, on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition. J Pharmacol Exp Ther. 2009;329(3):928-37.
39. Bono P, ElfvingH,Utriainen T, Osterlund P, Saarto T, Alanko T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol. 2009;20(2):393-4.
40. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20(2):227-30.
41. Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer. 2011;104(4):599-604. This is the most convincing study suggesting that hypertension may predict the outcome of bevacizumab-containing chemotherapy.